StreetInsider.com News Articles

Form 8-K Aptevo Therapeutics Inc. For: Oct 14

Wed, 14 Oct 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20261014/27184491.html

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Wed, 14 Oct 2026 08:46:00 -0400

SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

Aptevo's presentation will feature its broader CD40-directed multispecific portfolio and the Company's approach to bringing together two critical arms of the immune system - innate

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Wed, 14 Oct 2026 08:46:00 -0400

Aptevo's presentation will feature its broader CD40-directed multispecific portfolio and the Company's approach to bringing together two critical arms of the immune system - innate

Form S-8 Aptevo Therapeutics Inc.

Fri, 25 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260925/27107388.html

Form 8-K Aptevo Therapeutics Inc. For: Sep 24

Thu, 24 Sep 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260924/27099187.html

Aptevo targets IND-enabling studies for APVO451 in first half of 2027

Thu, 24 Sep 2026 08:05:39 -0400

Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company, announced progress on its trispecific cancer therapy programs, with plans to begin Investigational New Drug (IND)-enabling studies for its lead candidate, APVO451, in the first half of 2027.

According to a company statement, Aptevo is currently optimizing several trispecific candidates for scalable manufacturing, which the company describes as a necessary step before human testing can begin.

Trispecific therapies are engineered molecules designed to perform three functions simultaneously — recognizing cancer cells, activating an immune response, and countering cancer's defense mechanisms — within a single molecule.

Peter Pavlik, PhD, Senior Director of Protein Engineering at

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Thu, 24 Sep 2026 08:05:00 -0400

SEATTLE, WA / ACCESS Newswire / September 24, 2026 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced progress in its next-generation trispecific programs. The Company is optimizing several trispecific candidates for reliable, scalable manufacturing, an essential step toward future human testing. Aptevo expects to enter Investigational New Drug ("IND") enabling studies for the lead candidate, APVO451, in 1H2027.

Trispecific therapies are gaining attention across cancer drug development as researchers explore their potential

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Thu, 24 Sep 2026 08:05:00 -0400

Trispecific therapies are gaining attention across cancer drug development as researchers explore their potential

Form 8-K Aptevo Therapeutics Inc. For: Sep 22

Wed, 23 Sep 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260923/27097161.html

Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial

Thu, 03 Sep 2026 08:06:58 -0400

Aptevo Therapeutics Inc. (Nasdaq: APVO) reported a 93% clinical benefit rate in a small group of frontline acute myeloid leukemia (AML) patients with TP53 mutations treated with its mipletamig drug candidate in combination with venetoclax and azacitidine, according to a company statement.

Of 14 evaluable patients treated with the triplet combination, 13 experienced clinical benefit. Eleven patients, or 79%, achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), including nine complete remissions.

The company compared the 79% CR/CRi rate to a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated

Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial

Thu, 03 Sep 2026 08:06:58 -0400

The company compared the 79% CR/CRi rate to a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Thu, 03 Sep 2026 08:05:00 -0400

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment.

"TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Thu, 03 Sep 2026 08:05:00 -0400

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

"TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk

Form D Aptevo Therapeutics Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981557.html

Form D Aptevo Therapeutics Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981557.html

Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26961603.html

Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26961603.html

Aptevo Therapeutics files prospectus for resale of 6.4M shares

Fri, 21 Aug 2026 16:13:07 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) filed a prospectus related to the potential resale of up to 6,444,858 shares of common stock, par value $0.001 per share, by certain selling stockholders.

The shares are issuable upon the exercise of three types of warrants: pre-funded common stock purchase warrants covering up to 861,708 shares, common stock purchase warrants covering up to 4,308,540 shares, and inducement warrants covering up to 1,274,610 shares.

The pre-funded warrants and common warrants were issued through a private placement under a Securities Purchase Agreement dated August 12, 2026. The inducement warrants were issued pursuant to Warrant Inducement and Reload Letters,

Aptevo Therapeutics files prospectus for resale of 6.4M shares

Fri, 21 Aug 2026 16:13:07 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) filed a prospectus related to the potential resale of up to 6,444,858 shares of common stock, par value $0.001 per share, by certain selling stockholders.

Form S-1 Aptevo Therapeutics Inc.

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961484.html

Form S-1 Aptevo Therapeutics Inc.

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961484.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961376.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961376.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929119.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929119.html